Genentech Sues Rivals Over Generic Anti-Viral Drug Plans

Law360, Washington (September 5, 2013, 3:29 PM EDT) -- Genentech Inc. and a unit of parent company Roche Holding Ltd. sued Mylan Pharmaceuticals Inc. and an Actavis Inc. unit Wednesday in Delaware federal court, accusing their rivals of infringing a patent covering anti-viral Valcyte with their planned generic versions of the drug.

Genentech and Roche Palo Alto LLC say that Mylan and Watson Laboratories Inc.–Florida’s planned generic versions of valganciclovir hydrochloride — a 450-milligram tablet for Mylan and a 50-milligram-per-milliliter oral solution for Watson — infringe U.S. Patent Number 6,083,953 covering Valcyte.

   

“On information...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.